InMed Pharmaceuticals Inc.
INM
NASDAQ·Healthcare·Drug Manufacturers - Specialty & Generic·Mkt cap $7.3M
$1.33
▲ 0.00%
P/E
—
Mkt Cap
$7.3M
52-Wk Range
$0.58–$2.50
52-Week Range
$0.58 - $2.50
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 40.6% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary IntegraSyn biosynthesis manufacturing platform for pharmaceutical-grade cannabinoids
- First-mover advantage in clinical-stage cannabinoid therapeutics with multiple pipeline programs
- Focused approach on high-unmet-need indications with less competitive landscapes
- Strategic partnerships and research collaborations enhancing development capabilities
Bear Case
1 risk
- Average volatility.
Growth
No forward estimates available
Clinical trial progression of INM-755 with potential FDA approval pathway
Value
Valuation data unavailable
Momentum
Weak
-17.4% over 3m
Quality
Thin
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying INM right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
SEP 23, 2026
Reported EPS of -$1.43 vs -$94.44 consensus (+98.5% surprise). Revenue of $2.1B vs $2.1B expected (0.0%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+98.5%
Revenue trend · last 8Q
—
—
—
+8%
+39%
-11%
+1%
-100%
Q4 24
Q1 24
Q2 24
Q3 25
Q4 25
Q1 25
Q2 25
Q3 26
$1.3M
$1.3M
$1.1M
$1.3M
$1.8M
$1.1M
$1.1M
$0
Margins · last 8Q
Gross
—
Operating
—
Profit
—
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How INM stacks vs Drug Manufacturers - Specialty & Generic
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related